Elanix Biotechnologies AG: capital increase successfully placed, gross issuing proceeds amount to some EUR 4.76 million
Elanix Biotechnologies AG: capital increase successfully placed, gross issuing proceeds amount to approx. EUR 4.76 million
THE INFORMATION CONTAINED IN THIS DISCLOSURE IS NOT INTENDED FOR PUBLICATION OR DISSEMINATION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN
Potsdam, 24 February 2017 - On 30 January 2017 Elanix Biotechnologies AG (Frankfurt Stock Exchange: ELN, "Elanix", "Company") has resolved to implement a capital increase against cash contribution from authorized capital by up to 1,133,200 New Shares, offering an indirect subscription right to shareholders.
All 1,133,200 New Shares have been fully placed within the scope of the preemptive rights offering and a private placement. The capital increase was oversubscribed due to the high level of interest, hence subscriptions had to be re-allotted equally.
The subscription price per New Share amounted to EUR 4.20. In total the gross placement volume amounts to approx. EUR 4.76 million which will be used to cover the operational expenses of the Company and the further development of marketing the Company's main product GynRepair(R), which is already available in Switzerland, within the European Union as of Q2 2017.
Tomas Svoboda, CEO
Contact / Investor Relations
Maria Widowski E-mail: email@example.com Telephone number: +49 331 583 945 10
Elanix Biotechnologies (Frankfurt: ELN) develops and commercializes tissue regeneration products for acute wound care, dermatological and gynecological applications, and provides services in cell technologies. The company was founded in 2013 as a spin-out from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix owns GMP certified Master and Working cell banks with vast quantities of cells of different cell types.
The Company is headquartered in Nyon, Switzerland, with offices in Potsdam, and is listed on the Frankfurt stock exchange under the symbol ELN. For more information and updates, visit www.elanix-biotechnologies.com.
This publication contains forward-looking statements subject to certain risks and uncertainties. Actual results may be materially different from those expressed or implied by such statements due to a variety of risk factors and uncertainties such as changes in the business, economic and competitive situation, exchange rate fluctuations, uncertainties regarding litigation or investigation proceedings and the availability of financial resources. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Elanix Biotechnologies AG disclaims any obligation to update these forward-looking statements.
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Elanix Biotechnologies AG. This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in the United States of America (the "United States"), Australia, Canada or Japan or in any jurisdiction to whom or in which such offer or solicitation is unlawful. The securities referred to in this announcement will not be and have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act") and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements under the U.S. Securities Act. Subject to certain exceptions, the securities referred to in this announcement may not be offered or sold in Australia, Canada or Japan, or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan. The offer and sale of the securities referred to in this announcement has not been and will not be registered under the U.S. Securities Act or under the applicable securities laws of Australia, Canada or Japan. There will be no public offer of the securities in the United States.
This announcement also does not constitute a prospectus within the meaning of the EU Directive 2003/71/EC of the European Parliament and of the Council of 4 November 2003 as amended ("Prospectus Directive").
24-Feb-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.deLanguage: English
Company: Elanix Biotechnologies AG Domstr. 22 14482 Potsdam
Germany ISIN: DE000A0WMJQ4 WKN: A0WMJQ Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf End of Announcement DGAP News Service
547579 24-Feb-2017 CET/CEST